Literature DB >> 16419974

HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node.

Tomohide Tsukahara1, Satoshi Kawaguchi, Kazunori Ida, Sigeharu Kimura, Yasuaki Tamura, Tatsuru Ikeda, Toshihiko Torigoe, Satoshi Nagoya, Takuro Wada, Noriyuki Sato, Toshihiko Yamashita.   

Abstract

Malignant fibrous histiocytoma (MFH) of the bone is a high-grade sarcoma characterized histologically by the composition of fibroblasts and pleomorphic cells with a prominent storiform pattern. Despite institution of multi-modality treatments, the prognosis for patients with this tumor remains unsatisfactory. In the present study, towards the goal of developing active immunotherapy for those affected, we established four cell lines from a 53-year-old woman who suffered from MFH of the humerus with lymph node metastases. MFH2003 and MFH2003-B7.1 were the primary lesion-derived cell line and its B7.1-transfectant, respectively. B2003-EBV and TIL2003 were a B cell line established from peripheral blood lymphocytes and a T cell line established from tumor-invaded lymph nodes, respectively. MFH2003 cells could be maintained over a period of 1 year in vitro, and could be xenotransplanted into nude mice. The phenotype of cells analyzed by immunostaining was similar to the original tumor. TIL2003 cells were all CD8+ and specifically recognized MFH2003 cells and MFH2003-B7.1 cells, but not B2003-EBV cells. An anti-HLA-class I monoclonal antibody completely blocked the anti-MFH2003 response of TILs2003. These findings indicate the existence of an anti-MFH specific immune response in the microenvironment of metastatic lymph nodes. The present autologous cell lines provide the basis for identification of novel tumor-associated antigens and may be helpful in the establishment of immunotherapy for patients with MFH of the bone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16419974     DOI: 10.1002/jor.20019

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  5 in total

1.  Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.

Authors:  Tomohide Tsukahara; Makoto Emori; Kenji Murata; Takahisa Hirano; Norihiro Muroi; Masanori Kyono; Shingo Toji; Kazue Watanabe; Toshihiko Torigoe; Vitaly Kochin; Hiroko Asanuma; Hiroshi Matsumiya; Keiji Yamashita; Tetsuo Himi; Shingo Ichimiya; Takuro Wada; Toshihiko Yamashita; Tadashi Hasegawa; Noriyuki Sato
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

2.  A quest for therapeutic antigens in bone and soft tissue sarcoma.

Authors:  Satoshi Kawaguchi; Takuro Wada; Tomohide Tsukahara; Kazunori Ida; Toshihiko Torigoe; Noriyuki Sato; Toshihiko Yamashita
Journal:  J Transl Med       Date:  2005-08-08       Impact factor: 5.531

3.  Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B.

Authors:  Emi Mizushima; Tomohide Tsukahara; Makoto Emori; Kenji Murata; Asuka Akamatsu; Yuji Shibayama; Shuto Hamada; Yuto Watanabe; Mitsunori Kaya; Yoshihiko Hirohashi; Takayuki Kanaseki; Munehide Nakatsugawa; Terufumi Kubo; Toshihiko Yamashita; Noriyuki Sato; Toshihiko Torigoe
Journal:  Cancer Sci       Date:  2019-11-29       Impact factor: 6.716

4.  Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas.

Authors:  M Murase; M Kano; T Tsukahara; A Takahashi; T Torigoe; S Kawaguchi; S Kimura; T Wada; Y Uchihashi; T Kondo; T Yamashita; N Sato
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

5.  High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma.

Authors:  Makoto Emori; Tomohide Tsukahara; Masaki Murase; Masanobu Kano; Kenji Murata; Akari Takahashi; Terufumi Kubo; Hiroko Asanuma; Kazuyo Yasuda; Vitaly Kochin; Mitsunori Kaya; Satoshi Nagoya; Jun Nishio; Hiroshi Iwasaki; Tomoko Sonoda; Tadashi Hasegawa; Toshihiko Torigoe; Takuro Wada; Toshihiko Yamashita; Noriyuki Sato
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.